News | 14 November 2025
Pfizer completes up to $10 billion acquisition of Metsera
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Subscribe To Our Newsletter & Stay Updated
